Shares of Aquestive Therapeutics Inc (NASDAQ:AQST) have received a consensus broker rating score of 1.33 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.
Brokers have set a 12-month consensus price objective of $28.67 for the company and are predicting that the company will post ($0.49) EPS for the current quarter, according to Zacks. Zacks has also given Aquestive Therapeutics an industry rank of 87 out of 255 based on the ratings given to its competitors.
A number of research analysts recently commented on AQST shares. BMO Capital Markets started coverage on shares of Aquestive Therapeutics in a research note on Monday, August 20th. They set an “outperform” rating on the stock. JMP Securities started coverage on shares of Aquestive Therapeutics in a research note on Monday, August 20th. They set an “outperform” rating and a $29.00 price objective on the stock. Royal Bank of Canada started coverage on shares of Aquestive Therapeutics in a research note on Monday, August 20th. They set an “outperform” rating and a $23.00 price objective on the stock. Finally, Wedbush started coverage on shares of Aquestive Therapeutics in a research note on Wednesday, September 12th. They set an “outperform” rating and a $33.00 price objective on the stock.
NASDAQ AQST opened at $14.90 on Friday. Aquestive Therapeutics has a 12 month low of $13.61 and a 12 month high of $20.70. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of -1.16.
Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Tuesday, September 4th. The company reported ($1.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($1.66). The company had revenue of $13.93 million for the quarter. On average, equities analysts expect that Aquestive Therapeutics will post -0.93 earnings per share for the current year.
In related news, Director Douglas K. Bratton acquired 165,000 shares of the stock in a transaction that occurred on Tuesday, July 24th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $2,475,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Read More: Index Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.